Showing 3551-3560 of 5773 results for "".
- Harrow Completes Acquisition of US Rights to Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-closes-acquisition-of-us-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-and-will-begin-receiving-net-profit-payments-for-acquired-products/2481361/Harrow announced the closing of its previously announced acquisition with Novartis of the exclusive US commercial rights to five branded ophthalmic products: Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. In December, Harrow announced it had 
- Outlook Therapeutics Appoints Surendra Sharma, MD, and Glen Olsheim to Leadership Positionshttps://modernod.com/news/outlook-therapeutics-appoints-surendra-sharma-md-and-glen-olsheim-to-leadership-positions/2481359/Outlook Therapeutics announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence. “Outlook Therapeutics is very happy to welcome Surendra and Glen to our growing executive leadership te
- CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Boardhttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board/2481355/CXL Ophthalmics announced that Jonathan Talamo, MD, has been appointed as its new Chair of the Board of Directors. Dr. Talamo has served as a Board member for the company since 2020. CXLO is developing a minimally-invasive treatment for ectatic corneal disease. The company's Ep
- Bausch + Lomb Acquires AcuFocushttps://modernod.com/news/bausch-lomb-acquires-acufocus/2481353/Bausch + Lomb announced it has acquired AcuFocus, maker of the IC-8 Apthera IOL. Financial terms of the deal were not disclosed. The moves bolsters Bausch + Lomb's cataract surgery portfolio. AcuFocus' IC-8 was approved by the FDA in July
- CORE Names Its “Top 10 of 2022” Scientific Papershttps://modernod.com/news/core-names-its-top-10-of-2022-scientific-papers/2481351/Ahead of the first global eye care conference of the year, the Centre for Ocular Research & Education (CORE) has announced its “Top 10 of 2022” publications list, designating works of significant value to clinicians, researchers, educators, and manufacturers. The papers
- Eyenovia: Positive Evidence that Optejet Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Dropshttps://modernod.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatm
- Visus Therapeutics Appoints Eric D. Donnenfeld, MD, to Board of Directorshttps://modernod.com/news/visus-therapeutics-appoints-eric-d-donnenfeld-md-to-board-of-directors/2481347/Visus Therapeutics announced the appointment of Eric D. Donnenfeld, MD, to the company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert in refractive, cornea, and cataract surgery. “I am thrill
- Rayner Launches ‘Peer2Peer: The Podcast’ for Clinical Educationhttps://modernod.com/news/rayner-launches-peer2peer-the-podcast-for-clinical-education/2481342/Rayner announced the launch of the latest addition to their Peer2Peer clinical education platform, "Peer2Peer: The Podcast." Topics included in the podcase include the do's and don’ts of implanting toric IOLs; marketing your clinic online; popular
- Neurotech Pharmaceuticals Appoints Scott Hunter as Chief Commercial Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-scott-hunter-as-chief-commercial-officer/2481341/Neurotech Pharmaceuticals announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eye care experience across both rare disease and specialty markets. “Scott’s appointment as the company&rsquo
- Acelyrin Acquires ValenzaBio, Maker of Treatment Candidate for Thyroid Eye Diseasehttps://modernod.com/news/acelyrin-acquires-valenzabio-maker-of-treatment-candidate-for-thyroid-eye-disease/2481339/Acelyrin announced the acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction. Financial terms of the deal were not disclosed. The acquisition of ValenzaBi